
### [NCIT:C4665](http://purl.obolibrary.org/obo/NCIT_C4665)
**Label:** Plasma Cell Neoplasm

**Subclasses:** [NCIT:C4734](http://purl.obolibrary.org/obo/NCIT_C4734) (Non-Secretory Plasma Cell Myeloma), [NCIT:C7813](http://purl.obolibrary.org/obo/NCIT_C7813) (Refractory Plasma Cell Neoplasm), [NCIT:C7765](http://purl.obolibrary.org/obo/NCIT_C7765) (Osteosclerotic Plasma Cell Myeloma), [NCIT:C7149](http://purl.obolibrary.org/obo/NCIT_C7149) (Smoldering Plasma Cell Myeloma), [NCIT:C7812](http://purl.obolibrary.org/obo/NCIT_C7812) (Solitary Osseous Plasmacytoma), [NCIT:C9349](http://purl.obolibrary.org/obo/NCIT_C9349) (Plasmacytoma), [NCIT:C6932](http://purl.obolibrary.org/obo/NCIT_C6932) (Solitary Plasmacytoma), [NCIT:C4002](http://purl.obolibrary.org/obo/NCIT_C4002) (Extraosseous Plasmacytoma), [NCIT:C7241](http://purl.obolibrary.org/obo/NCIT_C7241) (Plasmacytoma-Like Post-Transplant Lymphoproliferative Disorder), [NCIT:C3242](http://purl.obolibrary.org/obo/NCIT_C3242) (Plasma Cell Myeloma), [NCIT:C7240](http://purl.obolibrary.org/obo/NCIT_C7240) (Plasma Cell Post-Transplant Lymphoproliferative Disorder), [NCIT:C7242](http://purl.obolibrary.org/obo/NCIT_C7242) (Plasma Cell Myeloma Post-Transplant Lymphoproliferative Disorder), [NCIT:C118421](http://purl.obolibrary.org/obo/NCIT_C118421) (Anaplastic Plasmacytoma), [NCIT:C3180](http://purl.obolibrary.org/obo/NCIT_C3180) (Plasma Cell Leukemia), 

**Class expressions from DL-Learner:**

- Thing 55.08%
- [NCIT:C41040](http://purl.obolibrary.org/obo/NCIT_C41040) (Lytic Bone Lesion) 52.56%
- [NCIT:C43260](http://purl.obolibrary.org/obo/NCIT_C43260) (Bone Lesion) and [NCIT:C77140](http://purl.obolibrary.org/obo/NCIT_C77140) (Clinical Test Result) 52.56%
- [NCIT:C35869](http://purl.obolibrary.org/obo/NCIT_C35869) (Radiologic Finding) and [NCIT:C43260](http://purl.obolibrary.org/obo/NCIT_C43260) (Bone Lesion) 52.56%
- [NCIT:C62108](http://purl.obolibrary.org/obo/NCIT_C62108) (Extraosseous Lesion) 51.28%
- [NCIT:C36113](http://purl.obolibrary.org/obo/NCIT_C36113) (Anaplastic Lesion) 51.28%
- [NCIT:C35371](http://purl.obolibrary.org/obo/NCIT_C35371) (Lytic Metastatic Bone Lesion) 51.28%
- [NCIT:C7057](http://purl.obolibrary.org/obo/NCIT_C7057) (Disease, Disorder or Finding) 44.49%
- [NCIT:C43260](http://purl.obolibrary.org/obo/NCIT_C43260) (Bone Lesion) 37.92%
- [NCIT:C41039](http://purl.obolibrary.org/obo/NCIT_C41039) (Localized Lesion) 36.64%
- [NCIT:C41039](http://purl.obolibrary.org/obo/NCIT_C41039) (Localized Lesion) and (not ([NCIT:C39013](http://purl.obolibrary.org/obo/NCIT_C39013) (Estrogen Receptor Regulation by CARM1 Pathway))) 36.64%
- [NCIT:C41039](http://purl.obolibrary.org/obo/NCIT_C41039) (Localized Lesion) and (not ([NCIT:C39011](http://purl.obolibrary.org/obo/NCIT_C39011) (Cardiac Hypertrophy Pathway))) 36.64%
- [NCIT:C41039](http://purl.obolibrary.org/obo/NCIT_C41039) (Localized Lesion) and (not ([NCIT:C3901](http://purl.obolibrary.org/obo/NCIT_C3901) (Compound Nevus))) 36.64%
- [NCIT:C41039](http://purl.obolibrary.org/obo/NCIT_C41039) (Localized Lesion) and (not ([NCIT:C39006](http://purl.obolibrary.org/obo/NCIT_C39006) (Bioactive Peptide Signaling Pathway))) 36.64%
- [NCIT:C41039](http://purl.obolibrary.org/obo/NCIT_C41039) (Localized Lesion) and (not ([NCIT:C39004](http://purl.obolibrary.org/obo/NCIT_C39004) (B-Cell Survival Pathway))) 36.64%


